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Ibrutinib positively modulates many T-cell subsets in chronic lymphocytic leukemia (CLL). To understand
ibrutinib’s effects on the broader landscape of immune cell populations, we comprehensively characterized
changes in circulating counts of 21 immune blood cell subsets throughout the first year of treatment in patients
with relapsed/refractory (R/R) CLL (n = 55, RESONATE) and previously untreated CLL (n = 50, RESONATE-2)
compared with untreated age-matched healthy donors (n = 20). Ibrutinib normalized abnormal immune cell
counts to levels similar to those of age-matched healthy donors. Ibrutinib significantly decreased pathologically
high circulating B cells, regulatory T cells, effector/memory CD4+ and CD8+ T cells (including exhausted and
chronically activated T cells), natural killer (NK) T cells, and myeloid-derived suppressor cells; preserved naive T
cells and NK cells; and increased circulating classical monocytes. T-cell function was assessed in response to Tcell receptor stimulation in patients with R/R CLL (n = 21) compared with age-matched healthy donors (n = 18).
Ibrutinib significantly restored T-cell proliferative ability, degranulation, and cytokine secretion. Over the same
period, ofatumumab or chlorambucil did not confer the same spectrum of normalization as ibrutinib in multiple
immune subsets. These results establish that ibrutinib has a significant and likely positive impact on circulating
malignant and nonmalignant immune cells and restores healthy T-cell function.

1. Introduction
Chronic lymphocytic leukemia (CLL) is the most common lymphoid
malignancy in the United States and Europe [1,2], and is characterized
by clonal expansion of malignant B cells. CLL is also characterized by
profound immune dysregulation, including changes in the balance of
T-cell subsets, chronic T-cell activation and exhaustion, changes in
expression of inhibitory molecules and cytokine secretion, and induction

of myeloid-derived suppressor cells (MDSCs) [3–6]. Impairment of
innate and adaptive immunity is associated with pathophysiological
changes of the underlying disease, and potentially leads to higher
infection risk, as observed in clinical practice [4]. Immune dysfunction
in CLL becomes more severe with increasing time from diagnosis and is
exacerbated with chemotherapy [3,4]. Thus, patients with relapse
d/refractory (R/R) CLL tend to present with profound immune sup
pression and are more prone to infections relative to earlier disease onset
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or previously untreated patients [7,8].
Ibrutinib is the only once-daily Bruton’s tyrosine kinase (BTK) in
hibitor to demonstrate significant progression-free survival (PFS) and
overall survival benefit compared with established chemotherapy/che
moimmunotherapy regimens in CLL/small lymphocytic lymphoma
(SLL) [9–14]. Infections have been observed in patients receiving ibru
tinib, occurring most commonly within the first 6 months and gradually
declining over time [8–10]. The subsequent decline of infection rates
suggests that ibrutinib treatment may improve immune competence
and/or that the gradual reduction in CLL disease burden by ibrutinib
allows normalization of non-neoplastic immune cell function [15,16].
Besides BTK, ibrutinib covalently binds to interleukin-2–inducible T-cell
kinase (ITK), a component of the T-cell receptor (TCR) signaling
pathway [17]. Through BTK and ITK binding, ibrutinib may exert
modulatory effects on B cells, MDSCs, mast cells, and T cells. Previous
studies have shown that ibrutinib positively impacts specific T-cell
subsets in CLL patients, increasing cytotoxic T-cell activation, sup
pressing regulatory T cells (Tregs), increasing TCR diversity, reducing
programmed cell death 1 (PD-1)/programmed death ligand 1 expres
sion, and normalizing inflammatory cytokines [15,18–21]. Mechanistic
data from a phase 2 study showed that ibrutinib alleviates the inflam
matory microenvironment in bone marrow, thereby decreasing immu
nosuppressive effects of CLL-B cells on macrophages and T cells [18,22].
However, ibrutinib’s effects on the broader landscape of immune blood
cell populations have not been fully described. To address this, we
comprehensively characterized ibrutinib-related changes in peripheral
immune cells and T-cell functions in patients with R/R or previously

untreated CLL enrolled in RESONATE or RESONATE-2, respectively.
2. Materials and methods
2.1. Clinical studies and patient samples
Samples were collected from patients with R/R CLL treated with
ibrutinib or ofatumumab in the phase 3 RESONATE study
(NCT01578707) [23] and from patients with CLL treated with first-line
ibrutinib or chlorambucil in the RESONATE-2 study (NCT01722487)
[24] (Fig. 1A). Detailed clinical methods have been previously described
[23,24]; both studies were approved by institutional review boards of
participating institutions and were conducted according to the princi
ples of the Declaration of Helsinki and International Conference on
Harmonization Good Clinical Practice guidelines. All patients provided
written informed consent.
We analyzed peripheral blood mononuclear cells (PBMCs) isolated
by Ficoll density gradient from blood samples collected at baseline
(pretreatment) and 1, 2–3, 5–6, 9, and 12 months post-treatment.
Healthy donor ranges (HDRs) were obtained from peripheral blood
samples from untreated, age-matched (> 50 years), healthy donors
(n = 20, for first-line immunophenotyping; n = 18, for R/R T-cell
function assessments), or from published reference values for healthy
donors aged > 50 years (R/R immunophenotyping) [25].

Fig. 1. Patient populations. (A) Complete study
design of RESONATE (R/R CLL) and
RESONATE-2 (first-line CLL) clinical trials. (B)
Baseline characteristics of patients studied. ALC:
absolute lymphocyte count; CT: computed to
mography; ECOG PS: Eastern Cooperative
Oncology Group performance status; FCR: flu
darabine + cyclophosphamide + rituximab;
CLL: chronic lymphocytic leukemia; IV: intra
venous; PD: progressive disease; R/R: relapsed/
refractory; SLL: small lymphocytic lymphoma.
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2.2. Flow cytometry immunophenotyping

months followed by a steady decrease over the subsequent 9 months
(Fig. 2A). T cells, NKT cells, and NK cells were also increased during
lymphocytosis (Fig. 2B-D-E, first-line CLL). With longer treatment,
ibrutinib restored abnormally elevated T-cell counts to within HDR
(Fig. 2B). NKT cells, important mediators of immune responses and
tumor immunosurveillance [30], were abnormally elevated in CLL pa
tients at baseline but were brought near HDR with ibrutinib treatment
(Fig. 2D). Despite initial lymphocytosis, median NK cell counts were
within HDR throughout ibrutinib treatment (Fig. 2E). Overall, patterns
of changes over time were similar between first-line and R/R cohorts. In
addition to lymphocytes, myeloid cells contribute to the tumor–immune
balance. Macrophages can adopt 1 of 2 divergent phenotypes in the
tumor microenvironment: M1 tumor-associated macrophages (TAMs)
have immune-boosting and cancer-killing potential and M2 TAMs are
immunosuppressive and promote tumor survival and spreading [31].
Because assessment for TAMs requires invasive biopsies, we investigated
their circulating precursors, classical and nonclassical monocytes, as
surrogates for M1 and M2 subsets, respectively [32]. Compared with
healthy donors, classical monocytes were significantly lower in CLL
patients (P < 0.0001; Fig. 2C, baseline). First-line ibrutinib progressively
restored classical monocyte counts to near HDR (Fig. 2C) and main
tained nonclassical monocytes (Supplementary Fig. S1C), whereas
chlorambucil significantly and persistently reduced classical monocyte
counts as well as NK- and T-cell counts (all P < 0.0001; Fig. 2B-C-E) to
below HDR. In effect, chlorambucil reduced all major circulating im
mune cells, while ibrutinib provided some normalization by decreasing
B, T, and NKT cells; increasing classical monocytes; and maintaining NK
cells throughout treatment.

PBMCs were thawed, washed, treated with Benzonase Nuclease
(Sigma-Aldrich, St. Louis, MO, USA), and prewarmed (1 h) before
staining with antibodies according to manufacturers’ recommendations
(Supplementary Tables S1 and S2). Circulating B cells, T cells, natural
killer (NK) cells, NKT cells, classical/nonclassical monocytes, and
monocytic MDSCs were identified using multiparametric flow cytometry
(Supplementary Table S3). Granulocytic MDSCs were not assessed
because they were likely removed during Ficoll separation. Cells were
acquired on FACSAria II and LSRFortessa X-20 flow cytometers (BD
Biosciences); analyses were performed with FlowJo software (BD Bio
sciences). Absolute counts were calculated by multiplying the frequency
of each population among total lymphocytes by absolute lymphocyte
counts (ALCs) obtained from whole-blood assessment on the day of
collection.
2.3. T-cell function assessment
Effects of treatment on T-cell proliferative ability, degranulation, and
cytokine secretion upon ex vivo TCR stimulation in the R/R CLL setting
were compared with healthy donors. PBMCs were stained with anti
bodies against CD3, CD4, CD8, CD19, annexin V, and LIVE/DEAD
fixable aqua dead cell stain (Supplemental Table S4) before and after 4
days of in vitro stimulation with 2.5 μg/mL anti-CD3 and 10 μg/mL antiCD28. T-cell proliferation was assessed at day 4 with carboxyfluorescein
succinimidyl ester (CFSE) staining. Lytic proteins and cytokines were
quantified in culture supernatant at day 3 using the LEGENDplex Human
CD8/NK panel (BioLegend, San Diego, CA, USA). To differentiate direct
treatment effects from indirect changes resulting from disease resolu
tion, we selected from each treatment arm similar numbers of re
sponders and non-responders at the 6-month timepoint (end of
ofatumumab treatment), based on investigator-assessed response per
International Workshop on Chronic Lymphocytic Leukemia criteria
[26].

3.2. Ibrutinib maintains Tnaive counts and normalizes the expanded
effector pool typically seen in CLL
T cells constitute a crucial component of adaptive immunity; a
competent immune system must gradually evolve T cells from the pool
of naive T (Tnaive) cells to fully differentiated effector memory cells.
When Tnaive cells encounter a cognate antigen, they undergo maturation
through distinct stages, including stem cell memory (TSCM), central
memory (TCM), transitional memory (TTM), effector memory (TEM), and
terminal effector memory (TTEM) [33,34]. Alterations to those stages
could compromise immune response [35]. The distribution of T-cell
developmental subsets is dysregulated in CLL patients, with elevated
terminally differentiated T cells and reduced Tnaive cells [5]. Similar to
data from Long et al. [15], we confirmed that the CLL-associated in
crease in T-cell counts was not equally distributed across T-cell devel
opmental stages (Fig. 3A-B, baseline). Early developmental stages (Tnaive
and TSCM) were low at baseline, particularly CD4+ Tnaive in R/R patients,
whereas later stages (TTM, TEM, and CD8+ TTEM), were highly elevated
relative to HDR. Ibrutinib significantly reduced effector and memory
T-cell counts toward HDR and preserved Tnaive (Fig. 3A-B). Normal TSCM
counts were also preserved, and high CD8+ TSCM counts in R/R CLL were
reduced to HDR with ibrutinib. These data show that ibrutinib
normalized pathogenically elevated T-cell counts from any develop
mental stage in both R/R and first-line cohorts. In contrast, chlorambucil
reduced T cells across all developmental stages, including the already
too low CD4+ and CD8+ Tnaive counts (Fig. 3B).

2.4. Statistical analysis
Statistical analyses were performed using GraphPad Prism8
(GraphPad Software, San Diego, CA, USA). Mann-Whitney 2-tailed test
was performed to compare cohorts (baseline CLL vs. healthy donors;
ibrutinib vs. comparators; R/R vs. first-line setting). Wilcoxon matchedpairs signed-rank test was used to determine statistically significant
changes versus baseline (pretreatment); P ≤ 0.05 was considered
significant.
3. Results
3.1. Ibrutinib treatment positively impacts critical circulating immune
cells
A competent immune system requires adequate presence and coor
dinated activities of innate and adaptive immune cells. Positive effects
on these immune cells may enhance CLL treatment effectiveness [3]. At
6 months, PFS rates were superior for ibrutinib versus ofatumumab in
RESONATE and versus chlorambucil in RESONATE-2 (88% vs. 65% and
98% vs. 78%, respectively). However, at this timepoint, reductions in
circulating total B-cell counts were smaller with ibrutinib (63% vs. 94%
and 58% vs. 97%, respectively) [23,24], showing that PFS improvement
does not solely correlate to the decrease in circulating tumor cells. We
performed immunophenotyping of PBMCs from patients in those trials
(Fig. 1B) to better characterize the impact of treatment on circulating
lymphocytes and myeloid cells, and to delineate differences between
first-line and R/R cohorts. As previously described [27–29],
ibrutinib-treated patients experienced transient lymphocytosis with an
increase in B cells that largely subsided to baseline levels within 3

3.3. Ibrutinib decreases pseudo-exhausted T cells and immunosuppressive
cell populations
T-cell exhaustion is characterized by increased anergy and dimin
ished immune responsiveness. Effector and memory T cells in CLL pa
tients are frequently pseudo-exhausted due to chronic activation by CLLB cells and interactions with other immunosuppressive cells, such as
Tregs and MDSCs [5,36,37]. Ibrutinib therapy is associated with sub
stantial reversal of T cell exhaustion [21]. In our study, elevated
numbers of dysfunctional or pseudo-exhausted T cells, encompassing
3
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Fig. 2. Ibrutinib restores major immune cell
populations to near healthy range. (A-E) Liquid
nitrogen cryopreserved peripheral blood
mononuclear cells from healthy donors, as well
as patients enrolled in RESONATE (ibrutinib
treatment) and RESONATE-2 (ibrutinib or
chlorambucil treatment) were analyzed by flow
cytometry to assess changes in immune cell
numbers during treatment. Changes in (A) B
cells, (B) T cells, (C) classical monocytes, (D)
NKT cells, and (E) NK cells counts in circulation
are reported. Data represent median and 95%
confidence intervals. HDRs are represented by
the interquartile range in blue or green, with
the median in dash line. The blue HDR repre
sents reference values for healthy donors aged
> 50 years as published by Bisset et al [25]. The
green HDR represents data from 20 heathy do
nors aged > 50 years (median 63.5 years;
range, 51-76), assessed along with samples
from RESONATE-2 in first-line CLL. Statistically
significant changes reported in this figure were
determined using Wilcoxon matched-pairs
signed rank test at the 12-month timepoint in
comparison to baseline (pretreatment) (*P <
0.05; **P < 0.01; ***P < 0.005; ****P <
0.001). CLL: chronic lymphocytic leukemia;
HDR: healthy donor range; Mono: monocytes;
NK: natural killer; NKT: natural killer T cell;
R/R: relapsed/refractory. (For interpretation of
the references to colour in the Figure, the
reader is referred to the web version of this
article).

exhausted T cells (Texh: PD-1+) and long-term activated T cells (TLTA:
CD38+HLA-DR+), are found before treatment (Fig. 4A-B). Notably,
CD4+ and CD8+ TLTA counts were 6-fold higher in R/R versus first-line
CLL (P < 0.0001; Supplementary Fig. S1B), likely resulting from pro
longed exposure to an immunosuppressive environment, extended
chronic stimulation, and possibly secondary effect of previous therapies.
Ibrutinib reduced both Texh and TLTA counts toward HDR in first-line
and R/R CLL (Fig. 4A-B), while chlorambucil lowered Texh cells only.
Elevated circulating Tregs have been observed in CLL and are asso
ciated with poor prognosis [38]. As previously reported for ibrutinib
treatment in R/R CLL [39], Tregs returned to healthy levels in the
first-line and R/R cohorts (Fig. 4C). MDSCs also exert immunosuppres
sive effects on T cells and expand with cancer progression, inflamma
tion, and infection [6]. Monocytic MDSCs were significantly decreased
by first-line ibrutinib treatment (Fig. 4D; not assessed in R/R CLL).

after thawing. Compared with healthy donors, CLL patients had 50%
more apoptotic CD4+ and CD8+ T cells at baseline (P < 0.0001; Fig. 5A).
After 6 months of treatment, ofatumumab did not significantly alter
T-cell apoptosis. In contrast, ibrutinib decreased T-cell apoptosis, espe
cially CD8+ T-cell apoptosis (P = 0.0103; Fig. 5B). No correlation was
observed with response, suggesting that the effect was not a by-product
of reduced disease burden. These data suggest that ibrutinib’s true effect
on apoptotic cells upon TCR stimulation is masked by Annexin V+ on
activated T cells.
Nonapoptotic cell death (NACD; annexin V– aquahi) fractions at
baseline in stimulated T-cell cultures were similar between CLL patients
and healthy donors (Fig. 5E). After 6 months of treatment, ibrutinib
decreased NACD post-TCR stimulation by 53% (Fig. 5F), while ofatu
mumab had no significant effect.
3.5. Ibrutinib improves T-cell proliferation potential

3.4. Ibrutinib improves T-cell survival

Upon antigen stimulation, clonal expansion of T cells is necessary for
a successful immune response. T-cell proliferation is impaired in CLL
patients [5] and this impairment may lead to immunodeficiency. To
assess T-cell proliferative ability, we stimulated PBMCs with
αCD3/CD28 for 4 days in vitro and measured T-cell division index.
Proliferative ability of T cells from most ibrutinib-treated patients
improved with treatment, whereas ofatumumab impaired CD4+ and
CD8+ T-cell proliferation (Fig. 6A). At 6 months (end of ofatumumab
treatment), T-cell proliferative ability in ofatumumab-treated patients
decreased by 49% from baseline (P = 0.0032) but improved by 28% in
ibrutinib-treated patients (P = 0.0012; Fig. 6B). During both treatments,
T-cell proliferation was greater for cytotoxic T cells than for helper T
cells; this finding is of significance given the crucial role of CD8+ T cells
in antitumor immunity. To delineate therapy-specific effects from
overall disease status, we assessed changes in T-cell proliferation within
response subgroups (Fig. 6C). At 6 months, T-cell proliferation was
greater in responders versus non-responders for ibrutinib (+39%

Tumor-specific T cells expand following TCR stimulation, but con
tract subsequently via mechanisms, such as activation-induced cell
death and programmed cell death [40]. We examined cell death induced
by ex vivo TCR stimulation in samples from R/R patients. The R/R
cohort was selected due to its higher TLTA count compared to first-line,
likely leading to more pronounced T-cell dysfunction. At baseline, me
dian ALC was comparable between ibrutinib and ofatumumab arms
(Fig. 1B), as were percentages of B and T cells (approximately 80% and
3%, respectively). Following TCR stimulation, T cells from CLL patients
had higher rates of apoptosis (annexin V+) at baseline compared with
healthy donors (P < 0.0001; Fig. 5C), consistent with a chronically
activated phenotype. Although both treatments reduced T-cell apoptosis
over time and independently of patient response, the effect with ofatu
mumab was more rapid (Fig. 5D). To better understand whether ibru
tinib’s effect on apoptotic cells could be masked by annexin
V+–activated T cells [41,42], we assessed T-cell apoptosis immediately
4
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Fig. 3. Ibrutinib preserves early T-cell develop
ment stages, while reducing abnormally elevated
effector/memory populations. T-cell populations
were analyzed by flow cytometry in (A) R/R CLL
and (B) first-line CLL. Data represent median and
95% confidence intervals. Healthy donor range
(HDR) is represented by the interquartile range in
green and median in dash line. The HDR repre
sents data from 20 heathy donors aged > 50 years
(median 63.5 years; range, 51-76), assessed along
with samples from RESONATE-2 in first-line CLL.
Statistically significant changes reported in this
figure were determined using Wilcoxon matchedpairs signed rank test at the 12-month timepoint
in comparison to baseline (pretreatment) (*P <
0.05; **P < 0.01; ***P < 0.005). CLL: chronic
lymphocytic leukemia; CM: central memory; EM:
effector memory; HDR: healthy donor range; R/R:
relapsed/refractory; SCM: stem cell memory; TM:
transitional memory; TEM: terminal effector
memory. (For interpretation of the references to
colour in the Figure, the reader is referred to the
web version of this article).

Fig. 4. Ibrutinib reduces abnormally elevated
pseudo-exhausted T cells and immunosuppres
sive cells. Dysfunctional T-cell populations, such
as (A) exhausted PD-1+ T cells and (B)
chronically/long-term activated T cells (CD38+
HLADR+), were analyzed by flow cytometry,
along with immunosuppressive (C) Tregs and
(D) monocytic MDSCs. Data represent median
and 95% confidence intervals. HDR is repre
sented by the interquartile range in green and
median in dash line. The HDR represents data
from 20 heathy donors aged > 50 years,
assessed along with samples from RESONATE-2
in first-line CLL. Statistically significant changes
reported in this figure were determined using
Wilcoxon matched-pairs signed rank test at the
12-month timepoint in comparison to baseline
(pretreatment) (*P < 0.05; **P < 0.01; ***P <
0.005; ****P < 0.001). CLL: chronic lympho
cytic leukemia; HDR: healthy donor range; LTA:
long-term activation; mMDSCs: monocytic
myeloid-derived suppressor cells; PD-1: pro
grammed cell death 1; R/R: relapsed/refractory;
Texh: exhausted T cells; Tregs: regulatory T
cells. (For interpretation of the references to
colour in the Figure, the reader is referred to the
web version of this article).
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Fig. 5. Ibrutinib increases T-cell survival in R/R CLL. T-cell apoptosis (A-D) was assessed with annexin V by flow cytometry immediately after thawing, which
indicates the unstimulated status (A, B), and post 4 days of anti-CD3/CD28 stimulation (C, D). T-cell nonapoptotic cell death was also assessed by flow cytometry
after 4 days of anti-CD3/CD28 stimulation (E-F). Baseline statuses were compared to healthy donors (A, C, E), and treatment effects normalized to each patient’s
individual baseline are reported over time (B, D, F). Data represent median and interquartile range. Treatment-specific statistically significant changes were assessed
at the 6-month timepoint in comparison to baseline using Wilcoxon matched-pairs signed rank test, and only statistically significant changes are reported (*P < 0.05;
**P < 0.01). CLL: chronic lymphocytic leukemia; HD: healthy donors; NACD: nonapoptotic cell death; OFA: ofatumumab; R/R: relapsed/refractory; TCR: Tcell receptor.

vs. + 6%; P = 0.0078) and ofatumumab (–20% vs. –96%; P = 0.0371),
suggesting that disease resolution correlates with T-cell proliferation.
However, T-cell proliferation was significantly higher for ibrutinib than
for ofatumumab in both responders and non-responders, indicating that
ibrutinib improved T-cell proliferative ability beyond improvements
related to disease burden. Increased proliferation did not correlate with
T-cell or B-cell counts, nor with lymphocytosis status.

function of CD8+ T cells, was impaired in R/R CLL patients compared
with healthy donors (Fig. 6F). At 6 months, TCR-induced degranulation
of lytic proteins exhibited similar improvement in both treatment arms,
except for granzyme-B, which improved to a greater extent with ibru
tinib (Fig. 6G). At month 12, improvements in cytokine release and lytic
protein degranulation observed with ibrutinib were maintained and
degranulation was largely restored to HDR. These improvements did not
correlate with patient response or T-cell counts, suggesting that they
were therapy-specific.

3.6. Ibrutinib improves T-cell effector function

4. Discussion

Impairment in T-cell effector function is a key characteristic of CLL
[5,37]. Normally, upon antigen recognition and costimulatory signals,
effector T cells release an array of cytokines and lytic proteins to
potentiate immune responses. Cytokines further support T-cell matura
tion and proliferation, and attract fresh macrophages, neutrophils, and
other lymphocytes to attack infected or cancerous cells. Lytic proteins,
such as granzyme-A, granzyme-B, granulysin, and perforin, are
responsible for degranulation and lysis of targeted cells [33,34]. To
further characterize ibrutinib’s impact on T-cell effector function, we
quantified cytokines and lytic proteins released into the supernatant
following 3 days of in vitro TCR stimulation with PBMCs from R/R pa
tients treated with ibrutinib or ofatumumab. At baseline, less cytokine
release was observed in the ibrutinib arm (Fig. 6D-E), suggesting greater
immune dysfunction, which correlates with the higher prevalence of
poor prognostic features in this group (Fig. 1B). Compared with healthy
donors, R/R CLL patients at baseline had impaired secretion of IL-4, IL-6,
IL-10, and IL-17A but enhanced secretion of IL-2 and tumor necrosis
factor α (TNF-α) (Fig. 6D-E). Six months post-treatment, ofatumumab
only significantly improved secretory ability of IL-6 and IL-17A
(Fig. 6E). In contrast, almost all cytokines measured (IL-4, IL-6, IL-10,
IL-17A, and TNF-α) were significantly increased with ibrutinib at 6
months and stabilized thereafter (Fig. 6D). Degranulation of
granzyme-A, granzyme-B, granulysin, and perforin, a key effector

Single-agent ibrutinib has shown superiority over established ther
apies in patients with CLL/SLL in both the first-line and R/R settings
[9–14]. Patients enrolled in RESONATE and RESONATE-2 differ sub
stantially with respect to number of prior therapies (median 3 vs. 0,
respectively), cytogenetics, and other prognostic factors. Accordingly,
we considered it important to characterize these cohorts separately to
fully understand treatment effect and time to immune recovery in each
cohort. We comprehensively assessed the effects of ibrutinib on circu
lating immune cell counts and select functions over a 12-month period.
All ibrutinib-treated patients in the current analysis were
progression-free throughout this time frame. When appropriate, obser
vations were compared with randomized comparator treatments
(chlorambucil or ofatumumab) and healthy donor samples to under
stand and differentiate CLL disease-related effects. Functional analyses
were performed in R/R CLL patients only, as these patients are expected
to have more pronounced T-cell dysfunction than previously untreated
patients. Additionally, R/R patients were further evaluated based on
clinical response per iwCLL criteria to explore treatment-related effects
compared with indirect effects of disease resolution, although it should
be noted that clinical response may not fully correlate with disease
burden. Together with other reports [15,18–21], the current results
6

I.G. Solman et al.

Leukemia Research 97 (2020) 106432

(caption on next page)

7

I.G. Solman et al.

Leukemia Research 97 (2020) 106432

Fig. 6. Ibrutinib increases T-cell proliferation and restores T-cell function in R/R CLL. Cells were stained with CFSE prior to TCR stimulation with anti-CD3/CD28 for
4 days. (A-C) Cell division index was calculated based on dilution of the CFSE signal measured by flow cytometry and represent the average number of cell divisions
that a cell in the original population has undergone [division index = sum (i * N(i) / 2^i) / sum (N(i) / 2^i), where “i” is division number (undivided = 0), and “N(i)”
is the number of events in division “i”]. Treatment effects over time are normalized to each patient’s individual baseline. Division indexes for CD4+ and CD8+ T cells
(A) are reported, along with overall T-cell division indexes for ibrutinib and ofatumumab treatment at 6 months, the end of ofatumumab treatment (B). T-cell division
index at 6 months post-treatment was compared between responders (partial response with or without lymphocytosis, PR/PR-L) and non-responders (stable disease,
SD) based on investigator-assessed response per iwCLL criteria (C). (D-E) Cytokine and lytic protein concentrations in the supernatants of ex vivo PBMC cultures were
measured by LEGENDPlex assay after 3 days of anti-CD3/CD28 stimulation. Cytokines produced from (D) the ibrutinib cohort and (E) the ofatumumab cohort at
baseline and 6-12 months post-treatment. Baseline from both cohorts were found to be different and therefore data from each cohort are individually compared to
age-matched healthy donors. (F-G) Lytic proteins produced from both ibrutinib and ofatumumab cohorts were similar at baseline and are compared to healthy donors
(F). Over time changes in degranulation are reported normalized to each patient’s individual baseline (G). Data represent median and interquartile range. Statistically
significant changes reported in this figure were determined using Wilcoxon matched-pairs signed rank test at the 6-month timepoint in comparison to baseline
(pretreatment) (*P < 0.05; **P < 0.01; ***P < 0.005). CFSE: carboxyfluorescein succinimidyl ester; CLL: chronic lymphocytic leukemia; IL: interleukin; iwCLL:
International Workshop on Chronic Lymphocytic Leukemia; OFA: ofatumumab; PBMC: peripheral blood mononuclear cell; PR/PR-L: partial response without or with
lymphocytosis; R/R: relapsed/refractory; SD: stable disease; TCR: T-cell receptor; TNF-α: tumor necrosis factor α.

show that ibrutinib offers a unique protective and restorative effect on T
cells compared to other treatments.
An existing pool of Tnaive cells is needed to initiate adaptive immu
nity when tumorigenic or infectious antigens are encountered. Tnaive cell
counts are near HDR in previously untreated patients but significantly
lower in R/R patients (P = 0.0091; Supplementary Fig. S1A). Our data
showed that Tnaive cell counts were protected under ibrutinib, but
decreased under chlorambucil in the first-line cohort. Another study
reported reduced Tnaive cells following treatment with alemtuzumab or
fludarabine/cyclophosphamide [36]. Long et al. previously described
preservation of Tnaive cells during the first 5 months of ibrutinib treat
ment [15]; our analyses affirmed that this preservation continued over
12 months. Ibrutinib had no impact on Tnaive counts and they remained
overall below healthy donor levels. Long et al. also described increased
effector and effector memory T cells during ibrutinib treatment in R/R
patients with persistent lymphocytosis [15], a finding that seemingly
contradicted an earlier report [18] of decreased T cells at 6–12 months
in a mixed first-line and R/R cohort. By including timepoints encom
passing periods studied by both groups, we confirmed that the impact of
ibrutinib on T cells differs during the lymphocytosis period (typically the
first few months on treatment) relative to subsequent months. The initial
increase in effector, effector memory and exhausted T cells was only
observed during lymphocytosis, followed by a decrease and ultimately
normalization with continued ibrutinib treatment. Ibrutinib is thought
to induce lymphocytosis by preventing CXCR4-mediated homing of
CLL-B cells to lymph nodes [43]. Consequently, T cells previously under
co-opted pressure by CLL-B cells are also released from lymph nodes
[18]. In the circulation, without constant stimulation by CLL-B cells T
cells stop proliferating and some are eliminated, resulting in reduction
and normalization of overall T-cell count [22].
Unlike the first-line setting where CD8+ TSCM counts were normal at
baseline, the abnormally high level of CD8+ TSCM in R/R patients was
reduced. Normalization of T-cell subsets across T-cell development
stages, coupled with improved T-cell proliferative ability, suggest that
ibrutinib supports repopulation and functional recovery of the adaptive
immune system. Compared with ofatumumab, ibrutinib-treated patients
in our study carried more risk factors associated with poor prognosis,
including del(17p), del(11q), and a greater number of prior treatments
(Fig. 1B) [2]. Results of T-cell functional analyses are thus unlikely to be
biased in favor of ibrutinib. Our data indicate that 6 months of ibrutinib
treatment is required to significantly improve T-cell function, coinciding
with the timing of the decrease in infection rates observed in the clinical
setting [8,15]. Restoration of immunoglobulin A levels may also
contribute to the decline in infection rates after 6 months of ibrutinib
treatment [16]. Recent long-term analyses revealed that prevalence of
upper respiratory tract infection of any grade in RESONATE-2 was 13%
in the first year (n = 135), 7% in the second year (n = 123), and 8% in
the fifth year (n = 89) of ibrutinib treatment [9]. In RESONATE,
occurence of grade ≥ 3 infections gradually decreased from 29% in the
first year (n = 195) to 17% in the second year (n = 160) and 9% during

the sixth year of treatment (n = 57) [10]. Similar decreases in infection
rates following ibrutinib treatment were also observed in mantle cell
lymphoma [44]. The lower infection risk observed from these larger
cohorts indicates ibrutinib’s effect in multiple disease settings beyond
the small group of patients assessed here.
Cancer progression is facilitated by multiple mechanisms that
contribute to tumor evasion of the host immune system, including
accumulation of Tregs and MDSCs in the tumor microenvironment [40,
45]. Malignant CLL-B cells co-opt MDSCs, which impair T-cell function
by promoting expansion of Tregs [6]. Tregs and MDSCs together weaken
host immunity and support growth and survival of CLL-B cells and
opportunistic pathogens. Beyond this indirect effect on T cells, ibrutinib
may also influence them directly through ITK inhibition or other
mechanisms. In an ex vivo experiment, ibrutinib treatment was suffi
cient to reactivate exhausted cytolytic T-cell function in a co-culture of T
and CLL-B cells [46]. Attribution to ITK inhibition is supported by a
treatment-induced shift of CD4+ cells toward a tumor-suppressive Th1
phenotype, originally observed in αβ T cells [17] and more recently in
cytotoxic Vγ9Vδ2 T cells [47]. We hypothesize that, in the clinical
setting, ITK inhibition may also underlie the significant reduction in the
incidence and severity of infusion-related reactions (IRR) observed with
ibrutinib/obinutuzumab versus chlorambucil/obinutuzumab in the
iLLUMINATE trial (25% vs. 58% any grade IRR; 3% vs. 9% grade ≥ 3 or
serious IRR) [11]. Although conclusive data are not yet available, the
same mechanism also likely mitigates the incidence of severe
cytokine-release syndrome (CRS) observed with ibrutinib combined
with anti-CD19 chimeric antigen receptor T-cell infusion (JCAR014)
versus JCAR014 monotherapy (0% vs. 25% grade ≥ 3 CRS) [48]. In this
regard, the context-dependent effect of ibrutinib on T cells is particularly
intriguing: ibrutinib reactivates anergic T cells and improves engraft
ment [49] to enhance antitumor effect, but downregulates undesirable
inflammatory responses [48].
The samples derived from RESONATE and RESONATE-2 allowed us
to characterize the immune status of previously untreated and R/R CLL
patients. The R/R population, which reportedly has a higher rate of
infections than previously untreated patients [7,8], was found to have
more immune cell subsets with aberrant counts. For example, R/R pa
tients appear to have up to 3 times fewer CD4+ Tnaive cells and 5-fold
higher chronically activated TLTA cells compared with previously un
treated patients at baseline (Supplementary Fig. S1A-B). Overall, ibru
tinib treatment provided immune reconstitution for both cohorts.
Normalization was more complete in the first-line cohort though, in
regard to Tnaive, TLTA, and classical monocytes (Supplementary Fig. S1).
While chemoimmunotherapy-based regimens have been considered
standard care for first-line treatment of young, fit patients with mutated
IGHV, recent data from ECOG-ACRIN showed that ibrutinib/rituximab
improved PFS and overall survival, and reduced grade ≥ 3 infectious
complications compared with chemoimmunotherapy (20.3% with flu
darabine/cyclophosphamide/rituximab vs. 10.5% with ibrutinib/ritux
imab; P < 0.0001) [13]. Quantitative immunophenotype and functional
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data presented here support the hypothesis that improved clinical out
comes associated with first-line ibrutinib treatment are attributable, at
least in part, to this therapy’s beneficial immune reconstitution effects
when compared with chemotherapy-based regimens. In contrast, the
process of rebuilding the immune system is incomplete and lengthier if
patients have received prior therapies, such as chemotherapy-based
regimens, before ibrutinib.
Here, we comprehensively characterized changes in circulating
counts of 21 immune subsets as well as T-cell function throughout a full
year of treatment and demonstrate that ibrutinib has a significant,
progressively positive impact on both malignant and nonmalignant
immune cells in CLL. These positive effects on circulating nonmalignant
immune cells may contribute to long-term CLL disease control, overall
health status, and decreased susceptibility to infection.
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